Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chronic Renal Insufficiency Cohort (CRIC) Study Metabolomics and Proteomics

ABSTRACT: Chronic Renal Insufficiency Cohort (CRIC) Study Metabolomics and Proteomics

PROVIDER: PRJNA1134272 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Chronic Renal Insufficiency Cohort (CRIC) Study Metabolomics and Proteomics

Project description:Chronic Renal Insufficiency Cohort (CRIC) Study Metabolomics and Proteomics

| PRJNA1134273 | ENA

Chronic Renal Insufficiency Cohort (CRIC) GWAS

Project description:Chronic Renal Insufficiency Cohort (CRIC) GWAS

| PRJNA171879 | ENA

Chronic Renal Insufficiency Cohort Study (CRIC)

Project description:<p>The Chronic Renal Insufficiency Cohort (CRIC study) was established in 2001 by the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) to improve the understanding of the relationship between chronic kidney disease and cardiovascular disease. The goals of the CRIC Study are to examine risk factors for progression of chronic kidney disease and cardiovascular disease among patients with chronic kidney disease and to develop predictive models to identify high-risk subgroups, informing future treatment trials and increasing application of available preventive therapies.</p>

| phs000524 | dbGaP

Homo sapiens

Project description:Chronic Renal Insufficiency Cohort (CRIC) GWAS

| PRJNA171880 | ENA

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Chronic Renal Insufficiency Cohort Study (CRIC)

| phs000524.v1.p1 | EGA

Proteomics of CKD progression in the chronic renal insufficiency cohort.

Project description:Progression of chronic kidney disease (CKD) portends myriad complications, including kidney failure. In this study, we analyze associations of 4638 plasma proteins among 3235 participants of the Chronic Renal Insufficiency Cohort Study with the primary outcome of 50% decline in estimated glomerular filtration rate or kidney failure over 10 years. We validate key findings in the Atherosclerosis Risk in the Communities study. We identify 100 circulating proteins that are associated with the primary outcome after multivariable adjustment, using a Bonferroni statistical threshold of significance. Individual protein associations and biological pathway analyses highlight the roles of bone morphogenetic proteins, ephrin signaling, and prothrombin activation. A 65-protein risk model for the primary outcome has excellent discrimination (C-statistic[95%CI] 0.862 [0.835, 0.889]), and 14/65 proteins are druggable targets. Potentially causal associations for five proteins, to our knowledge not previously reported, are supported by Mendelian randomization: EGFL9, LRP-11, MXRA7, IL-1 sRII and ILT-2. Modifiable protein risk markers can guide therapeutic drug development aimed at slowing CKD progression.

| S-EPMC10564759 | biostudies-literature

Integrated Analysis of Transcriptomics, Proteomics and Metabolomics Data Reveals the role of SLC39A1 in Renal Cell Carcinoma

Project description:Integrated Analysis of Transcriptomics, Proteomics and Metabolomics Data Reveals the role of SLC39A1 in Renal Cell Carcinoma

| PRJNA860598 | ENA

Combined analysis of metabolomics, proteomics, and transcriptomics to identify biomarkers for resistant hypertension

Project description:Combined analysis of metabolomics, proteomics, and transcriptomics to identify biomarkers for resistant hypertension

| PRJNA990810 | ENA

Combined analysis of metabolomics, proteomics, and transcriptomics to identify biomarkers for resistant hypertension

Project description:Resistant hypertension (RH) has emerged as a formidable challenge in the realm of hypertension prevention and treatment, owing to its potential for causing severe target organ damage. The identification of biomarkers assumes paramount significance in unraveling the pathogenesis of RH and facilitating early diagnosis and treatment. Despite the conduct of several single omics studies on RH, the intricate pathogenesis of this condition remains only partially understood. In this study, we comprehensively analyzed metabolomics, proteomics, and transcriptomics on healthy individuals, hypertensive patients, and those with RH. A variety of substances were screened, as potential diagnostic markers for RH. The hypoxia-inducible factor-1 (HIF-1) signaling pathway was identified as the pathogenic signaling pathway for RH. In conclusion, this study provides multi-omics analysis information to enhance our understanding of the pathogenesis of RH and to explore potential diagnostic markers, providing new insights for the search for effective therapeutic targets.

2025-02-05 | GSE236442 | GEO

Proteomics and metabolomics in renal transplantation-quo vadis?

Project description:The improvement of long-term transplant organ and patient survival remains a critical challenge following kidney transplantation. Proteomics and biochemical profiling (metabolomics) may allow for the detection of early changes in cell signal transduction regulation and biochemistry with high sensitivity and specificity. Hence, these analytical strategies hold the promise to detect and monitor disease processes and drug effects before histopathological and pathophysiological changes occur. In addition, they will identify enriched populations and enable individualized drug therapy. However, proteomics and metabolomics have not yet lived up to such high expectations. Renal transplant patients are highly complex, making it difficult to establish cause-effect relationships between surrogate markers and disease processes. Appropriate study design, adequate sample handling, storage and processing, quality and reproducibility of bioanalytical multi-analyte assays, data analysis and interpretation, mechanistic verification, and clinical qualification (=establishment of sensitivity and specificity in adequately powered prospective clinical trials) are important factors for the success of molecular marker discovery and development in renal transplantation. However, a newly developed and appropriately qualified molecular marker can only be successful if it is realistic that it can be implemented in a clinical setting. The development of combinatorial markers with supporting software tools is an attractive goal.

| S-EPMC4006577 | biostudies-other

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data